MICROGRAVITY RESEARCH SERVICES BUSINESS PLAN

I. Executive Summary

Company Description

The company is a U.S.-based research-as-a-service provider launching in 2026; its legal and commercial name is currently undisclosed and the name origin is not provided. We operate in the commercial space R&D sector, offering a turnkey platform that lets pharmaceutical, biotech, and materials science firms run experiments in microgravity. Our core services include experiment design consultation, payload integration in ISO-7 clean rooms, launch logistics, in-orbit operations, and secure data retrieval. One-liner: We remove technical and bureaucratic barriers to orbital research so clients can focus on science.

We run a state-of-the-art facility with ISO-7 clean rooms and space-environment testing tools and manage end-to-end project workflows from protocol validation to certified sample return. What sets us apart is the full-service model combined with affordable pricing tiers and rapid turnaround tailored to small and mid-size R&D teams. Target customers are U.S. and international pharma, biotech, and advanced materials firms conducting proof-of-concept or preclinical studies. Short-term goals: validate 12 customer missions in year one and achieve 60% gross margin on lab services. Long-term goals: scale to 100 missions annually by 2030 and expand to persistent orbital platforms. One-liner: We aim to democratize zero-gravity R&D through accessible, reliable, end-to-end services.

Problem

Cutting-edge pharmaceutical and materials-science research requires microgravity access, but current options are costly, complex, and restricted to a few elite institutions. Researchers face multi-year waits, heavy bureaucracy, and steep costs, which delay validation, inflate budgets, and limit experimental frequency.

Existing solutions leave startups, most universities, and commercial teams underserved: access is concentrated, episodic, and technically burdensome. There is a clear market gap for an affordable, frequent, commercial-grade gateway to space-based research.

Solution

Groundbreaking drug-discovery and materials-science work is blocked by the high cost, complexity, and slow timelines of current microgravity access; researchers and small firms lack agile, transparently priced partners, and that bottleneck prevents products that require space conditions. One line: this service removes the access barrier so scientists can focus on results, not logistics.

We provide a turnkey research-as-a-service platform for end-to-end experiment management in microgravity. Services include experiment design, payload integration with flight hardware, mission scheduling and recovery logistics, secure data retrieval, and post‑flight analysis. By 2026 the platform will offer a standardized pathway for U.S.-based firms to access microgravity conditions. One line: we handle the flight work so researchers focus on science.

Mission Statement

To empower global innovators by providing the most accessible, reliable, and transparent gateway to microgravity research, accelerating the development of life-changing products for the benefit of humanity.

Key Success Factors

Success derives from specialized engineering, dependable launch access, proprietary integration, focused markets, and tight financial control.

• Specialized team: aerospace engineers and scientists bridging spaceflight and lab research.
• Reliable launch partnerships: strategic agreements with leading launch and platform providers.
• Proprietary integration tech: payload software and standardized hardware that cut technical risk and ops cost.
• Targeted market focus: prioritizing pharmaceuticals where microgravity yields clear competitive advantage.
• Financial discipline: operating plan targets break-even within 16 months for sustainability.

Financial Summary

This section summarizes the five-year financial outlook: strong revenue growth to $12.08M by 2030, an initial EBITDA loss in 2026, and sustained profitability thereafter.

Financial requirements: initial funding to cover negative cash through Apr-27 (minimum cash -$629k). The model assumes billable rates of $350–$550/hour and marketing spend of $150k in 2026 rising to $300k in 2028. Expected return: payback in 37 months, IRR 4.32%, ROE 10.98%.

Overall outlook: revenue scale and improving margins lead to sustained profitability and investor payback within three years.

Funding Requirements

We require USD 1,500,000 to fund immediate CapEx, recruit the initial expert team, and cover operating losses until break-even in April 2027.

Financial snapshot: Year 1 revenue of USD 1,368,000, Year 5 revenue of USD 12,080,000; initial 2026 EBITDA loss of USD 715,000, profitability in 2027 with EBITDA USD 393,000, and 2030 EBITDA of USD 5,958,000; break-even Apr-2027 and full payback in 37 months, using billable rates of USD 350–550/hour.